trending Market Intelligence /marketintelligence/en/news-insights/trending/IRbTwAo6r8vWQXqjIlOupg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi-Regeneron's Dupixent wins EU nod for skin disease in adolescents

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sanofi-Regeneron's Dupixent wins EU nod for skin disease in adolescents

Sanofi and Regeneron Pharmaceuticals Inc. said the European Commission approved Dupixent for treating adolescent patients with a certain skin disease.

The extended approval allows the use of Dupixent, or dupilumab, to treat moderate-to-severe atopic dermatitis in patients aged 12 to 17 years who are candidates for systemic therapy. Atopic dermatitis is a common chronic inflammatory skin disease characterized by red and itchy skin.

Dupixent is the first biologic medicine approved in the EU to treat these patients.

The extended approval was backed by results of the Liberty AD clinical program in which patients treated with Dupixent demonstrated at least 75% improvement in the disease's extent and severity. Additionally, 42% of patients showed 75% or greater skin improvement compared to placebo.

In the U.S., Dupixent is already approved for the same indication, as well as to treat chronic rhinosinusitis with nasal polyps and as an add-on maintenance therapy for moderate-to-severe asthma in certain patients.

Tarrytown, N.Y.-based Regeneron and France's Sanofi are evaluating Dupixent in a range of clinical development programs for diseases driven by allergic and other kinds of inflammation.